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The condition has long been deemed to be difficult in its diagnosis and treatment. Even 
dating over 2000 years back, sepsis has already been described by historians and 
philosophers alike. In the present day, a definition for sepsis is still a constantly evolving 
work in progress [1], hotly debated in order to facilitate physicians in identifying and treating 
this critical illness. While many advances have been made in modern medicine, the 
mechanisms of disease and definitive treatment options remain elusive.   
 
Earliest understandings of sepsis can be summarized as blood poisoning, the body’s 
response to an infection with massive release of cytokines. This knowledge is still reflected 
in the present day definitions where inflammation is a hallmark of the disease and 
laboratory values signal the body’s readiness in mounting an attack. The progression of the 
disease eventually leads to organ failures and death. There is no simple diagnostic tool for 
sepsis. Other than treating the infection, most therapy options are largely supportive. The 
prevalence of sepsis has gone up in the developed world and its mortality rate rivals that of 
myocardial infarction [2]. 
 
Despite advances in current medical therapies, the prognosis remains poor. Sepsis is 
associated with a mortality rate at around 10 – 20 %, this increases dramatically with severe 
sepsis (20 – 50 %) and septic shock (40 – 80 %) [3]. These extremely ill patients with severe 
sepsis and septic shock are the focus in this thesis. Efforts are continuously being made to 
improve the outcomes for this patient population. Despite being a significant challenge, this 
mysterious and fascinating illness is of great interest in the field of critical care medicine, a 
reflection of the complexities of the human immune system.  
 
 
1.2. Selenium and oxidative stress 
 
Critically ill patients, such as those suffering from severe sepsis, have considerable oxidative 
stress [4], a major promoter of systemic inflammation and organ failure through the 
production of excessive free radicals or a depletion of antioxidation defense mechanisms. 
Exogenous antioxidant supplementation has long been practiced by physicians when 
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treating critical illnesses, which has shown some positive effects especially for those at high 
risk of death [5]. Selenium, among other vitamins and trace elements, is one such well 
known antioxidant.  
 
The body’s battalion of antioxidant defense mechanisms include superoxide dismutase, 
catalase and glutathione peroxidase, which require trace elements for a functional enzyme 
to mop up free radical species in protecting cells from oxidative stress [6]. An inflammatory 
state also causes a loss of the intestinal mucosal integrity, which impairs absorption of 
essential nutrients in combatting oxidative stress [7]. The serum concentrations of trace 
elements suffer a significant decrease during sepsis and severe illness, and remain low for 
quite a period of time [8]. This trace element deficiency in sepsis patients may simply be a 
reflection of malnutrition but whether supplementation reduces mortality is unclear. 
European ICUs tend to be more liberal and North Americans more restrictive in 
administering trace elements to their patients [9]. 
 
 
1.3. Immune function during sepsis 
 
Canadian physician Sir William Osler was a pioneer in modern medicine and made the 
observation that patient with sepsis did not die from the disease itself, but rather, from the 
own body’s mounted immune response to infection. This is a double edged sword where a 
suitably mounted immune response is essential in getting rid of an infection, but on the 
other hand, too much inflammation causes irreparable damage to the host [10].  
 
As discoveries are being made about the complex disease evolution in sepsis, the systemic 
inflammatory response syndrome (SIRS) remains a hallmark of the diagnosis. This entails the 
innate immune system being overactivated, where a pro-inflammatory cascade ensues, 
triggering cytokine, chemokine, complement and mediator release, as the body’s defense 
against infection [11]. More recently in the literature, the opposite phenomenon of SIRS has 
been increasingly described – an inhibition of the immune system known as immune 
paralysis or compensatory anti-inflammatory response syndrome (CARS) [12, 13]. In fact, at 
the onset of severe sepsis, the immune system appears to be in a state of anergy which 
poses a significant susceptibility to secondary infections in these already critically ill 
individuals [14]. Lymphocyte apoptosis and a shift from the TH1-dominated to the TH2-
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dominated state contribute to this immune paralysis. The interplay between 
hypoinflammation and hyperinflammation in the pathogenesis of sepsis is poorly 
understood. In fact, a third theory suggests that both these mechanisms are concurrently at 
play, known as the mixed anti-inflammatory response syndrome (MARS) [15].  
 
There are many unknowns in the disease process. Whether mortality is attributed to the 
uncontrolled pro-inflammatory response or rather the later immunosuppressive state makes 
therapy decisions extremely difficult. The immune response can be desirable or detrimental 
at different stages of sepsis. Depending on the initial infection focus, different arms of the 
innate and adaptive immune system can be recruited, including a complex network of 
mediators and regulatory mechanisms. These small signaling molecules that are released by 
lymphocytes are called cytokines. They are implicated in all aspects of the cascade resulting 
in inflammation and are released by specific cell types as well as short lived. Therefore, 




1.4. Selenium as possible immune booster 
 
Selenium is a vital nutrient with immunological, antioxidant and anti-inflammatory 
properties, which is also the cornerstone of the antioxidation defense mechanism [16]. 
Selenoenzymes play an important role in oxidation-reduction signaling, free radical 
scavenging and immune system responses [17]. There have been many systemic reviews 
and meta-analyses which demonstrated positive mortality benefits of selenium in sepsis 
patients, especially at higher intravenous dosages [18, 19, 20, 21, 22, 23]. Nevertheless, the 
most recent and largest randomized controlled prospective trial on selenium monotherapy 
in severe sepsis (SISPCT) did not find improved survival as compared to the placebo group 
[24].  
 
Despite many selenium supplementation studies in sepsis patients having examined 
mortality as an endpoint, our aim was to elucidate the effects of selenium on immune 
function [25]. With the help of a conventional immune cytokine assay using whole blood 
samples from sepsis patients, we can uncover and monitor the immune function at multiple 
time points during the disease course. 
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1.5. Scope of Study 
 
Building on the results of previous trials which have largely yielded no mortality benefits 
from sodium selenite in severe sepsis patients in the intensive care setting, it is our intention 
to further elucidate possible immunological effects of this medication. To this end, we 
centered our study based on three key questions. The first being whether selenium 
administration alters the immune capabilities in this critically ill patient population with 
known severe immune dysregulation. Secondly, we hope to uncover potential differences in 
the various immune pathways through examining key cytokine responses using a diverse 
selection of stimuli. The third question is whether certain tendencies towards hypo or 
hyperinflammatory states can be associated with early disease progression, using time 
points over a three-week course.  
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2. Materials and methods 
 
2.1. Trial Design 
 
2.1.1. SISPCT Study 
 
The patient population at our hospital was recruited under the larger randomized clinical 
trial “Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial 
Therapy in Severe Sepsis” (SISPCT https://clinicaltrials.gov/ct2/show/NCT00832039), where 
33 German hospitals participated in. Primary and secondary outcomes were analyzed in this 
double blinded study to examine the effects of high dose sodium selenite infusions and 
procalcitonin guided antimicrobial therapy on the mortality and morbidities of sepsis 
patients in an intensive care setting. The enrolment period was from November 2009 until 
June 2013 with a 90-day follow-up period. The primary end point was mortality at 28 days 
and secondary outcomes included 90-day all-cause mortality, secondary infections, days 
without intervention, cost of antimicrobial and days without antibiotic use.  
 
 
2.1.1.1. Inclusion and exclusion criteria 
 
For enrolment in the SISPCT study, patients were stringently evaluated based on detailed 
predetermined guidelines which qualify them for either severe sepsis or septic shock. The 
sepsis diagnosis can be made with a laboratory proven infection focus or a high degree of 
clinical suspicion in combination with at least two of the SIRS criteria, as listed in Table 1 
below. Sepsis definitions have since undergone two rounds of updates internationally and 
the criteria discussed in the SISPCT study were based on the most up to date guidelines at 
the time of study design. SIRS with an infection focus in combination with acute organ 
failure was defined as severe sepsis. Sepsis in addition to arterial hypotension or need for 













Table 1. Criteria for sepsis and related conditions. 
Condition Definition  
Systemic inflammatory 
response syndrome (SIRS) 
At least two of the following conditions present: 
• Hypothermia (< 36°C) or hyperthermia (> 38°C) 
• Tachycardia (> 90 bpm) 
• Tachypnea (> 20/min) or PaCO2 < 33 mmHg or 
mechanical ventilation 
• Leukopenia (WBC < 4000 cells/mm3) or leukocytosis 
(> 12000 cells/mm3) or > 10% immature cells 
Sepsis SIRS and confirmed or presumed infection. 
Severe sepsis Sepsis with organ dysfunction. 
Septic shock Severe sepsis with refractory hypotension. 
Multiple organ dysfunction 
syndrome (MODS) 
Evidence of more than two organ systems failing. 
Adapted from the dissertation of Lars Sudhoff [26] and the 1992 ACCP/SCCM Consensus Conference 
definitions [27]. 
 
Mechanical ventilation (i.e. Intubated patients) overrides the criteria of an increased 
respiratory rate or decreased PaCO2. To qualify for severe sepsis or septic shock, patients 
need to additionally demonstrate at least one dysfunctional organ system on top of sepsis. 
The specific criteria are listed below in Table 2 and were made by the admitting medical 
team. In order to qualify for the study, patients must be enrolled within 24 hours of their 
severe sepsis or septic shock diagnosis.  
 
Exclusion criteria of the study included pregnancy, lactation period, selenium intoxication, 
use of antibiotics for other chronic causes, discontinuation of therapy, terminal or palliative 
diagnosis, severe immune compromise (CD4+ counts < 200/mm3 or neutrophils < 500/mm3), 
medication induced immune compromise (i.e. after organ transplantion), clinical trial 
involvement in the past month, earlier participation in SISPCT or personal relations to the 









Table 2. Severe sepsis and septic shock. 
Clinical diagnosis Criteria  
Severe 
Sepsis 
Acute encephalopathy Pathologic alteration of global mental status in the 
absence of structural disease or substance use. 
Thrombocytopenia Thrombocytes ≤ 100,000/µl or decrease in thrombocytes 
> 30% within 24 hours with no acute blood loss. 
Renal insufficiency Urine output ≤ 0.5 ml/kg/h with adequate fluid infusion 
for over an hour or serum creatinine increase ≥ 2 above 
the reference range. 
Metabolic acidosis Base deficit > 5 mEq/l or serum lactate ≥ 1.5 above the 
reference range. 
Arterial hypoxemia Arterial oxygen partial pressure < 10 kPa (75 mmHg) on 
room air or Horowitz index ≤ 33 kPa (250 mmHg) with 
supplemental oxygen not due to pre-existing cardiac or 
pulmonary conditions. 
Arterial hypotension Systolic blood pressure ≤ 90 mmHg or mean arterial 
pressure ≤ 70 mmHg for > 1 hour despite adequate fluid 
resuscitation without other causes for circulatory shock. 
Septic shock Diagnosis of SIRS and 
proven or presumed infectious origin and 
systolic blood pressure ≤ 90 mmHg or mean arterial 
pressure ≤ 70 mmHg for > 2 hours despite adequate fluid 
resuscitation and necessitates vasopressor use. 
To be enrolled in the SISPCT trial, patients had to have severe sepsis or septic shock as well as meet the 
aforementioned inclusion criteria. Adapted from the dissertation of Lars Sudhoff [26]. 
 
 
2.1.1.2. Informed consent 
 
Written informed consent for the SISPCT study was obtained from 76 patients enrolled at 
Munich University Hospital. The study protocol was approved by the University of Jena 
Research Ethics Committee with local amendments (Eudra-CT-Nr. 2007-004333-42). In the 
case where the patient’s ability was impaired and no medical proxy had been identified, a 
positive declaration from a certified physician not involved in the patient’s treatment was 
obtained. This can be overturned once the patient was again capable or a substitute decision 
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2.1.1.3. SISPCT protocols 
 
The two solutions, placebo or sodium selenite, were administered immediately following 
enrolment for the entire stay in the intensive care unit. The randomization process was 
coordinated centrally in a double blinded fashion. Initially, a bolus was administered over 20 
minutes through the central line consisting of either 1000 µg of selenium, sodium selenite 
pentahydrate (selenase® T pro injection, biosyn Arzneimittel GmbH, Fellbach, Germany) in 
aqueous 0.9 % sodium chloride solution (50 ml total volume) or the 50ml aqueous 0.9% 
sodium chloride solution. The same concentration was then given slowly at 1000 µg of 
selenium over a 24-hour period or alternatively, the sodium chloride placebo solution. The 
continuous infusion lasted until discharge from ICU or for maximally 21 days.  
 
All other treatment decisions were made at the discretion of the medical team based on 
individual circumstances such as parenteral nutrition, antimicrobial or corticosteroid 
therapy. Patient clinical and laboratory parameters were recorded throughout the duration 
of the ICU stay, to a maximum of 21 days. Additional follow ups were conducted at days 28 
and 90. Patient blood sample collection took place on days 0, 1, 2, 3, 4, 5, 6, 7, 10, 14, and 
21. Study sample collections and interventions were carried out in addition to the routine 
care of the patients.  
 
The non-selenium part of the SISPCT study involved independently assigning patients 
randomly to either the procalcitonin guided antimicrobial therapy group or the control 
group. The details of the PCT algorithm, where plasma procalcitonin levels directed 
antimicrobial therapy, can be found in the original study. For the purposes of the present 
immune function study discussed here, procalcitonin measurements were independent of 








2.1.2. Immune function assays 
 
As an extension of the SISPCT study, we recruited a total of 76 patients at our center from 
June 2011 till February 2013 to participate in the immune function study. The randomization 
process was identical to that in the larger trial and additional blood samples were collected 
for cytokine stimulation assays. In our cohort, the centrally coordinated randomization led 
to 40 patients receiving sodium selenite and 36 receiving placebo.  
 
 
2.2. Cytokine responses 
 
2.2.1. Patient blood collection 
 
Blood samples were collected from an arterial catheter in most cases, if that was not 
available, blood was drawn from the central venous catheter. Ex vivo whole blood samples 
for the cytokine assays were taken on days 0, 4, 7, 14, and 21. Routine bloodwork carried 
out on the ICU by the treatment team was carefully documented and also made available 
anonymously for the study. In each case, 9ml of patient blood was drawn into a lithium-
heparinized tube (S-Monovette® 9 ml, Lithium-Heparin, 92x16 mm, Sarstedt AG & Co., 
Nümbrecht, Germany) and taken for further processing. 
 
 
2.2.2. Whole blood stimulation 
 
From the whole blood in lithium-heparinized tubes, 400 µl was transferred under aseptic 
conditions into tubes containing 400 µl of DMEM (Dulbecco´s Modified Eagle’s Medium 
Nutrient Mixture F-12 HAM, Sigma-Aldrich, Steinheim, Germany) and the various immune 
stimulating agents. As a control group, the basal cytokine release response was measured 
without any addition of inciting antigens. The total volume in each tube was 800 µl.  
Pokeweed mitogen (PWM) (Sigma-Aldrich, Steinheim, Germany) strongly activates B and T 
cell division in a receptor independent manner. Lipopolysaccharide (LPS) (E.coli serotype 
025:B6 Sigma-Aldrich, St. Louis, MO, USA) is an integral part of the outer gram-negative 
bacterial membrane and induces in animals a profound immune cascade. Phorbol myristate 
acetate and Ionomycin (PMA-I) (Sigma-Aldrich, St. Louis, MO, USA) stimulates cytokine 
production in immune cells through the protein kinase C (PKC) signaling pathway. A 
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CD3/CD28 mixture (Becton Dickinson, Franklin Lakes, NJ, USA) consisted of T cell receptor 
ligands which bind to major histocompatibility complexes on accessory cells. Additionally, 
influenza (1% Influvac, Solvay, Hannover, Germany), bacterial (1% Boostrix, GlaxoSmithKline, 
Munich, Germany), fungal (Candida lysate, Allergopharma, Reinbeck, Germany), and viral 
(CMV, EBV mixture, ABI, Columbia, SC, USA) stimulants were also used in our study as 
inciting agents. [25] 
 
 
2.2.3. Assay analysis 
 
Incubation of samples took place for 48 hours at body temperature (37°C) and the 
supernatant was subsequently frozen at minus 80°C for future analysis. For the processing at 
a later time point, samples were thawed and 200 µl of the supernatant mixture was 
withdrawn. The number of cytokines in the solution were analyzed using Luminex xMAP® 
technology (Bioplex®) and commercially sold reagents made by BioRad-Laboratories Inc. 
(Hercules, California, USA) in accordance with manufacturer instructions. The readouts were 






2.3.1. Data collection 
 
Clinical and laboratory data were recorded initially without identifying information using 
SPSS (IBM Crop., New York, USA). Day 0 was defined as the timepoint of inclusion into the 
study until 7 o’clock the following day and blood samples were taken as soon as possible 
following enrolment. Disease scores were also calculated and recorded as a reflection of 
patient illness severity including the Simplified Acute Physiology Score SAPS II and Acute 
Physiology And Chronic Health Evaluation APACHE II at Day 0. Cytokine data were included 
in the database upon completion of the assays. For concentrations under the assay 







2.3.2. Data analysis challenges 
 
The overall goal to “investigate whether the evolution of the marker values over time was 
different in the two treatment groups, selenium and placebo” [25], presents a significant 
statistical challenge due to missing data points. Given the nature of our patient population 
and the experimental settings, there was significant attrition in the 21 days as patients pass 
away or got transferred to the normal inpatient ward. There was also “potentially strong 
correlation of the measurements within patients, there were individuals with very high 
average values and individuals with very low average values” [25]. We had a sample size of 
76 at day 0, this number dropped significantly by the end of the study at day 21, to only 17 
patients. Those patients who passed away represented a population that was likely more 
severely diseased and those patients who were well enough to leave the ICU likely 
represented milder disease severities. “It is also important to note that these missing values 
in this cohort were not completely at random. Moreover, the measurements of each 
individual were usually noticeably correlated over time (i.e. with progressions in a more 
similar range to each other on average than measurements from another person). Given this 
correlation, standard linear regression could not be used to model this data. Selecting an 
appropriate statistical approach to accurately model the evolution of the datapoints over 
time while taking all these aforementioned considerations into account required advanced 
statistical tools.” [25] 
 
 
2.3.3. Generalized least squares (GLS) models 
 
In consultation with colleagues from the biostatistics department at our university, we 
decided to examine the “treatment effect on immune function over time by fitting 
generalized least squares (GLS) models with an unstructured correlation matrix.” [25] This 
approach provided the benefit of accounting for a certain degree of correlation between the 
residuals in the regression to avoid a potentially misleading inference. This method also 
avoided having to imputate or exputate missing values, which would cause significant 
skewing given our relatively small sample size. The statistical software R was used. “The R 
function ‘gls’ from the R package ‘nmle’ was applied to each log transformed marker 
successively with treatment and time (coded as factors) as well as their interaction as 
covariates. An assumption was made that the probability a missing value was determined by 
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the last observed values.” [25] This is realistic in our situation, for example, when a patient 
was recovering from sepsis, the laboratory values would tend to progressively trend 
relatively to previous values. This means we could yield a valid inference without imputation 
of the missing values. Additionally, correlations between measurements of each patient 
were accounted for. 
 
“The log transformation log(1+x) was used to better approximate normality as there were 
values close to zero. For each marker, the global null hypothesis of no interaction between 
treatment and time was tested using a likelihood-ratio test as implemented in the R function 
‘anova’. This analysis was repeated for 42 different combinations of inciting antigens and 
measured cytokines. Holm’s procedure was used to adjust for multiple testing. All statistical 







3.1. Study population 
 
3.1.1. Overall patient characteristics 
 
As a part of the larger clinical trial SISPCT, we recruited a total of 76 patients to be included 
in the immune function substudy at our intensive care units. Seven of which were either lost 
to follow up or retracted consent by the end of the 90-day study period. Six patients (8%) 
had a diagnosis of severe sepsis and 70 patients (92%) had septic shock at enrolment. 41 
patients (54%) were admitted through the medicine service (non-surgical) and 35 patients 
(46%) were admitted due to a primarily surgical intervention. Of the surgical patients, 27 
(36%) underwent unplanned operations and 8 (11%) were scheduled (elective and non-
elective) operations.  
 
Most common admission criteria included pneumonia (53%), intra-abdominal infections 
(19%) and urosepsis (7%). Approximately half of the patients had a microbiologically proven 
infection, from these 54% were gram-negative bacteria in origin, 38% gram-positive, and 8% 
viral.  The vast majority of which (96%) had received antibiotics at study begin and half had 
been started on hydrocortisone therapy (routinely used in septic shock patients who are 
hemodynamically fragile).  
 
In terms of patient outcomes, 26 (35%) required renal replacement therapy at some point 
during the ICU stay. The average number of days spent on the ICU was 11. The mortality rate 
of this subgroup while undergoing critical care was relatively low at 12% (8 patients) and the 




3.1.2.  Comparing the selenium and placebo groups 
 
With a grand total of 76 patients included at our hospital, 40 received infusions of sodium 
selenite and 36 sodium chloride solutions through the SISPCT study randomization (Table 3). 
The attrition rate over the 21-day period was comparable in both groups. The selenium arm 
began with 40 patients and dropped to 33 (at day 4), 24 (at day 7), 16 (at day 14), and 8 (at 
 
 14 
day 21) respectively. In the placebo arm, the 36 patients at enrolment went down to 28 (at 
day 4), 26 (at day 7), 16 (at day 14) and 9 (at day 21) respectively. Age, gender, weight, and 
height comparisons are listed also in the table below.  
 
Table 3.  
 
 
Taken from Table 1 in Guo et al. [25] Use with copyright permission from Elsevier. 
 
 
The selenium and placebo groups had comparably ill patients with similar simplified acute 
physiology score (SAPS II), acute physiology and chronic health evaluation (APACHE II), 
multiple organ dysfunction score (MODS) and sepsis-related organ failure assessment 
(SOFA) score. The mean arterial blood pressure and heart rate are physiological parameters 
that reflect disease severity in sepsis and whether adequate fluid resuscitation and/or 
pressor support has been initiated. C-reactive protein is a commonly used inflammatory 
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marker with huge variations in the critically ill. Serum lactate is a marker for tissue 




3.2. GLS analyses 
 
Overall the GLS analyses yielded no statistically significant immune function difference 
between selenium and placebo groups over time after adjustment for multiple testing (42 
combinations of inciting antigen and measured cytokine were tested). Because the 
assumption of constant variance was not satisfied in our data collection, we used the 
generalized least squares approach to account for inequalities of variance. The entirety of 
these results is tabulated in Section 9 and the corresponding visual representation of the 
data are included in the following results section. The x-axis demonstrates time progression 
(days 0, 4, 7, 14, and 21) for the two treatment groups, placebo and selenium. 
Logarithmically transformed longitudinal results (log (cytokine readout +1)) with the units 
picogram/mL are displayed along the y-axis. Despite the extremely widespread values and 
outliers, no individual datapoint was removed from the analysis to more closely model 
reality. Therefore, there are additional datapoints to be seen aside from the traditional box 





















Figure 1. Sample GLS analysis from R. 
 
After running the generalized least squares fit code in R using the datasets, regression 
coefficients were generated with accompanying p-values (a representative dataset is 
presented in Figure 1). The intercept, placebo group at day 0, was the comparison point to 
all later timepoints as well as the selenium group. These results were then tabulated and 
presented in excel tables including the p-values as well as box plots for all 42 combinations 
of reagents and cytokines. Representative tables are included below in the results section, 



















The stimulation assays in this group did not have any antigens to provoke the immune 
system and the cytokine responses were therefore a reflection of the unprovoked release 
found in patient blood samples. They were, as compared to assays with added antigens, 
logarithmically less. The values were concentrated between the log0 and log1 interval. There 
was also no discernable trend, either an increase or a decrease, over the 21-day period and 
no significant difference between the placebo and selenium groups. 
 
Table 4. No antigen addition immune assays (“basal”) with GLS model readouts from IL2, 








The analysis of variance (ANOVA) showed consistently large P-values, which suggests that 
the observed differences between treatment groups were likely due to random chance. 
There was no compelling evidence to reject the null hypothesis given the overwhelmingly 
non-significant P-values. The coefficients in the model represented an estimate of the 
change in the response variable for a one-unit change in a predictor variable. In our case, 
there were a number of predictor variables (treatment groups, time points, interaction of 
treatment and time point). All these predictors were treated as categorical variables in the 
model, so a one-unit change can be seen as whether or not a condition was present or 
absent. Given that the coefficients had large P-values, no significant relationship between 
individual predictors and the response can be concluded. This was seen in all test groups and 
the above table is a representative example for illustration. The placebo group Day 0 P-
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values were almost always approaching zero, because this coefficient represented the 
intercept in the model. This makes sense intuitively because the average cytokine response 
on Day 0 in the placebo group was significantly different from zero (the intercept).  
 
The cytokines examined without the addition of any inciting stimulating agent and their 
assay results are graphically displayed in Figure 2, which included interferon gamma (IFN), 
tumor necrosis factor alpha (TNF), and interleukin-2 (IL-2).  
 
Figure 2. Logarithmic cytokine release profiles using no stimuli (“basal”); A) interferon B) 
























3.2.2. CD3 / CD28  
 
The T-lymphocyte specific stimulators CD3 and CD28 partially mimic stimulation by antigen-
presenting cells in the body [28]. CD3 is a part of the T-cell receptor complex and CD28 co-
stimulation is necessary for activation. Without appropriate co-stimulation, the T-
lymphocytes would go down the anergic response pathway. This combination of antigens 
provides a reflection of the body’s acquired immune response.  
 
CD3 / CD28 proved to be a powerful stimulant in this case, demonstrating an active acquired 
immunity in sepsis patients. Many cytokines were investigated, none of which showed a 
statistically significant difference with respect to time or to the treatment groups. The 
cytokine release profiles from IL-2, IL-4, IL-5, IL-10, IFN, and TNF can be seen in Figure 3. 
 
Figure 3. Logarithmic cytokine release profiles using CD3 and CD28 as stimuli; A) interferon 
B) tumor necrosis factor C) interleukin-2 D) interleukin-4 E) interleukin-5 and F) interleukin-





3.2.3. Aspergillus  
 
Aspergillus is a fungus which can clinically cause severe disease, primarily through 
pulmonary infections. From an immune perspective, the innate immune response is largely 
involved given that in healthy individuals, cytokines drive the release and recruitment of 
neutrophils in order to clear this pathogen. It is therefore of particular significance in 
immunocompromised or severely ill patients [29]. The adaptive immune response also plays 
a role upon the exposure to airborne aspergillus species since fungal species are naturally 
found in the environment. 
 
This set of stimulation assays showed a somewhat dampened cytokine release profile with 
many outliers and a huge spread but no significant differences between the placebo and 
selenium groups. There were also no notable trends over time. The logarithmic plots from 
the cytokines IFN, TNF, and IL-2 are shown in Figure 4 below. 
 
Figure 4. Logarithmic cytokine release profiles using Aspergillus as stimuli; A) interferon B) 
















3.2.4. Bacteria  
 
The human innate immune system has evolved for hundreds of millions of years under the 
selective pressure of bacterial peptides, allowing the modern eukaryote to possess highly 
complex immune mechanisms. Yet, they are still built on common molecular strategies 
through the recognition of conserved microbial peptides by a wide range of pattern 
recognition receptors (PRRs) to signal the first line defenses [30, 31, 32]. These diverse PRRs 
simultaneously activate the innate and acquired immune responses by detecting pathogen-
associated (PAMPs) or danger-associated molecular patterns (DAMPs) in triggering the 
cytokine cascade.  
 
Bacterial components did yield a good response in the cytokine assays, especially 
interleukin-2. The response demonstrated a very slight tendency of increase between days 0 
and 7 followed by a slight decrease from days 7 to 21. There was no detectable difference 
between the placebo and selenium treatment groups. In Figure 5, the logarithmic data from 
IFN, TNF, and IL-2 are displayed as box plots respectively. 
 
Figure 5. Logarithmic cytokine release profiles using bacteria as stimuli; A) interferon B) 













3.2.5. Cytomegaly virus  
 
The human cytomegaly virus is an ancient herpes virus that has co-evolved with the immune 
system for a long time and rarely causes life-threatening symptoms in healthy individuals 
[33]. The host antiviral mechanisms implicate both the innate and adaptive compartments. 
Virus-infected monocytes differentiate into macrophages and are presented by the innate 
immune system to the pattern recognition receptors. The adaptive immune response to 
CMV is amongst the strongest in humans and actively engages the humoral and cellular 
responses [34]. 
 
The cytokine release assays with CMV showed a moderate response with some extremely 
high-valued outliers. In the placebo group, there was a trend for increased cytokine release 
over time, but this was not observed in the selenium group. Statistically significant 
differences were not detected amongst the treatment arms. The immune release assays 
measuring IFN, TNF, and IL-2 are shown below in Figure 6. 
 
Figure 6. Logarithmic cytokine release profiles using bacteria as stimuli; A) interferon B) 














3.2.6. Fungal components 
 
The ubiquitous exposure to fungi results in elaborate mechanisms to neutralize the 
pathogen for immune sufficient individuals. These responses engage both the innate and 
adaptive immune systems, producing an inflammatory response via the activation of nuclear 
factor kappa B and cytokines [35]. Binding to danger-associated molecular patterns DAMPs 
promote the activation of pathways that release substances due to tissue and cell damage, 
causing clinically significant disease in the immune compromised.  
 
The cytokine stimulation assays showed a moderate response. The selenium group had a 
slightly decreasing trend over time whereas the placebo group did not. There was no 
difference statistically between the selenium and placebo arms. The logarithmically 
transformed data can be seen graphically below in Figure 7 with readouts from IFN, TNF, 
and IL-2. 
 
Figure 7. Logarithmic cytokine release profiles using fungus as stimuli;  A) interferon B) 















3.2.7. Influenza  
 
Influenza viruses belong to a family of enveloped viruses which cause significant burden of 
respiratory diseases in the world. While the innate immune system rapidly responds to the 
initial infection, it then initiates the humoral immune system in producing antibodies and 
the cell-mediated immune system to activate helper and cytotoxic T-lymphocytes [36]. 
 
The influenza antigen elicited a moderate cytokine response in the whole blood ex vivo 
assay. There appeared to be an increased cytokine release over time in sepsis patients in the 
placebo group and an ever so slight decrease during the same period in the selenium group. 
We did not observe any differences statistically between the placebo and selenium groups. 
In Figure 8 below, the cytokine measurements using influenza as the inciting stimulus are 
shown with IFN, TNF, and IL-2 respectively. 
 
Figure 8. Logarithmic cytokine release profiles using Influenza virus as stimuli; A) interferon 

















3.2.8. Lipopolysaccharide  
 
Lipopolysaccharides (LPS) are large thermostable molecules with water and fat solubility 
embedded in the outer membrane of gram-negative bacteria. They help stabilize the 
membrane and generally elicit a strong immune response in humans. Their compositions are 
highly variable, which lead to a huge variation in their immunogenicity. LPS, also known as 
endotoxins, have been implicated in various disease processes such as endotoxemia, auto-
immune illnesses, cancer and obesity [37]. Lipopolysaccharides induced a very high cytokine 
count in the whole blood assays and a consistently strong response. There did not appear to 
have a time-axis dependent trend and no statistically significant difference was observed 
between the two groups. Six cytokine full blood assays stimulated with lipopolysaccharide 
are shown in Figure 9 with IL-1b, IL-6, IL-8, IL-10, IL-12, and TNF. 
 
Figure 9. Logarithmic cytokine release profiles using lipopolysaccharide as stimuli; 
A) interleukin-1b, B) interleukin-6, C) interleukin-8, D) interleukin-10, E) interleukin-12, and 






3.2.9. Phorbol myristate acetate and ionomycin  
 
Phorbol myristate acetate (PMA) is a potent tumor promotor often used in research 
contexts to activate the protein kinase C signal transduction pathway in studying 
carcinogenesis [38]. Used in combination with ionomycin, it can stimulate T-lymphocyte 
activation, proliferation, and cytokine production.  
 
Its strong immunogenicity is reflected in the assays with very robust cytokine release 
profiles. No particular trends were observed with respect to the time-axis. We found no 
difference statistically in the cytokine release profiles during the 21-day period between the 
selenium and placebo groups. The cytokine release assays are plotted logarithmically in 
Figure 10 with IFN, TNF, IL-2, IL-4, IL-5, and IL-10. 
 
Figure 10. Logarithmic cytokine release profiles using lipopolysaccharide as stimuli; 
A) interferon, B) tumor necrosis factor, C) interleukin-2, D) interleukin-4, E) interleukin-5, 






3.2.10. Pokeweed mitogen 
 
Pokeweed mitogen is a glycoprotein that strongly activates lymphocytes and stimulates the 
proliferation of B-cells, T-cells and plasma cells [39]. The small peptide triggers mitogenesis 
by uninhibiting checkpoint proteins in the cell cycle. 
 
An impressive immune response was seen in the whole blood assays with high cytokine 
readouts. The levels remained relatively unchanged over the entire 21-day period and there 
was again no significant difference between the place and selenium groups in the GLS 
analysis. The measurements collected from the cytokine assays using IFN, TNF, and IL-2 are 
shown in Figure 11. 
 
Figure 11. Logarithmic cytokine release profiles using pokeweed mitogen as stimuli; 




















Viruses are highly adaptable and they have evolved a truly complex relationship with the 
human immune system. One of the first line defences include natural killer and cytotoxic 
cells mediated by antigen presenting cells [40]. Interferons that are released by the immune 
system also directly interfere with, as the name suggests, a virus’ ability to replicate. 
Antibodies from B-lymphocytes facilitate agglutination and phagocytosis of infected cells, as 
a mechanism to rid the body of the pathogen.  
 
The immune assays demonstrated a mild to moderate response to viral antigens using blood 
samples of sepsis patients. No particular trend with respect to time can be noted and no 
statistical difference was seen between the treatment groups. The logarithmically 
transformed assay data are shown below in Figure 12 with the cytokines IFN, TNF, and IL-2. 
 
Figure 12. Logarithmic cytokine release profiles using viruses as stimuli; A) interferon B) 

















3.3. Statistical considerations  
  
3.3.1. Quantile-quantile plots 
 
To visually assess the normal distribution of the 42 investigated cytokine stimulation assays, 
we created individual quantile-quantile (Q-Q) plots. We ran the GLS statistical analysis based 
on the assumption that the dependent variable was normally distributed. These Q-Q plots 
were able to confirm that our data more or less conform to a normal distribution, 
reaffirming the validity of our model. Below are two samples of Q-Q plots created using the 
statistical software R for the data from LPS and IL-12 as well as PWM and TNFa (Figure 13). 
All 42 Q-Q plots had such a roughly straight line and reassured us of a normal distribution. 
 
LPS and IL-12      PWM and TNF 
Figure 13. Representative Q-Q plots in evaluating normal distribution. 
 
 
3.3.2. Holm method for multiple testing 
 
Statistical inferences are often made based on a predetermined acceptable level of 
probability, such as 0.05. Which is why significance levels are of great importance in testing 
a null hypothesis in the sciences, to accept or reject. There are, however, many situations 
such as this particular immune function study, where a large number of hypotheses were 
being tested simultaneously, in our case, 42. This contributes to a statistical challenge 
known as multiple comparisons, where the probability of incorrectly rejecting the null 
hypothesis dramatically increases. When 100 hypothesis are tested with a significance level 
of 0.05, around 5 will be significant due to multiple comparisons [41]. This false positive rate 





When all the whole blood assays with different combinations of inciting antigens and 
cytokines were run, we tested in effect 42 null hypotheses simultaneously where there was 
no difference in cytokine release over the 21-day period between the placebo and selenium 
groups. Indeed, we had a few statistically significant tests but once adjusted for the multiple 
comparisons, these effects were no longer. This demonstrated that between the placebo 
and selenium groups, we cannot discern a difference with respect to cytokine release 
profiles over time. In other words, there is no evidence of effect.  
 
The method we chose to account for multiple testing was Holm’s method, which is based on 
the Bonferroni method, where family-wise error rates (FWER) or type I errors are accounted 
for. Holm’s method “iteratively accepts and rejects hypotheses” by progressively adapting 
the threshold values [42], making it more powerful than Bonferroni’s method. After 
adjusting our results for multiple comparisons using Holm’s procedure, the null hypotheses 
could not be rejected anymore.  
 
 
3.3.3. Day 14 subgroup analysis 
 
In order to determine whether the severely ill sepsis patients benefited from selenium 
supplementation, we analyzed the subgroup of patients who stayed longer than 2 weeks in 
the ICU. The rationale behind this is that the extremely critically ill patients would be 
particularly immune compromised. However, there was no significant difference to be found 
between the selenium and placebo groups. This further reinforces the immune neutral 








4.1. The null hypothesis 
 
Building upon over two decades of past studies on selenium administration in an intensive 
care setting, the most recent systematic review and meta-analysis demonstrated no 
mortality benefits [43]. The cited studies were all conducted on ICU patients and consisted 
of 4044 patients in aggregate worldwide. Selenium was administered intravenously either as 
monotherapy or in combination with other antioxidative nutrients. Ultimately, there were 
no discernable effects provided through selenium supplementation on mortality, length of 
ICU stay, days on the ventilator, renal function, or infection rates. The majority of studies 
focused exclusively on septic patients, while some were a mixed population. There is no 
mistaking the importance of this highly lethal disease process, as clinicians and scientists are 
to this day searching for better therapies to improve patient outcomes. 
 
What these 21 randomized controlled trials did not investigate specifically was selenium’s 
effects on immunity, we sought to scrutinize exactly this immune response in our cohort of 
septic patients. Despite its reputation as an immune booster, patients with severe sepsis or 
septic shock receiving intravenous sodium selenite did not have an altered cytokine release 
profile over a 21-day observation period at the study site. Our immune function assays 
further supported the clinical findings of no mortality benefit and lend evidence to the 




4.2. Monitoring of immune modulation 
 
The pathophysiology of sepsis is until today not completely understood. The immune system 
mounts an overwhelming pro-inflammatory response in the beginning and often shifts to an 
immunosuppressive phase, where deaths occur due to secondary infections [44]. We were 
curious whether selenium would have an impact on the immune response and chose to 
monitor cytokine release during the disease process through a simple yet comprehensive 




A panel of cytokines were selected and their concentrations measured upon stimulation as a 
reflection of the overall immune function. Interferon gamma and tumor necrosis factor are 
known to transfer signals from T cells to infected cells in enhancing the killing mechanisms. 
Based on the assay results, IFN and TNF levels were not significantly altered with selenium 
supplementation, or in other words, the cytotoxic mechanisms were not boosted. The 
various interleukins (IL-1b, -2, -4, -5, -8, -10, and -12) all play important and specific roles in 
immune modulation and regulation. Therefore, a detection of significant trends in the 
release of particular cytokines could have revealed in which arm of the immune response 
selenium played a role. Such an effect was ultimately not found in any combination of 
antigens and cytokines after statistical adjustment. This could likely be due to the severe 
nature of the disease, the immune system is so intensely compromised that the therapy 
requires multiple measures. Additionally, whether the patients were facing a hyper- or 
hypoinflammatory state at the time of selenium administration is unclear. Given the delicate 
interplay between fighting off an infection and causing too much damage in the process, it is 
perhaps unlikely to expect a simple fix to a complex problem. 
 
 
4.3. Immunity and selenium 
 
While there have been many clinical trials conducted on the efficacy of selenium 
supplementation in the critically ill, not very much evidence is present on how the trace 
element directly affects the immune system. There are, however, a handful of studies which 
have shown that selenium promotes the proliferation of activated T cells and natural killer 
cell activity, as well as enhances cytotoxic lymphocyte mediated capabilities in targeting 
cancer cells [46, 47]. In mice models, differentiation of CD4+ T cells favored the Th1 
pathway, which leads to an increased cell-mediated response important in fighting 
intracellular bacteria and viruses, through dietary selenium supplementation [48]. Many of 
these studies were performed in elderly or cancer patients, both of which have a 
compromised immune system. Simple supplementation with 100µg selenium daily over a 6 
months period resulted in a stronger proliferative response to antigen challenge in an 
elderly study population [49]. Most of the positive immune effects of selenium can be 
attributed to the insertion of the element into selenoproteins, 25 of which have been 




The immune function in severe sepsis patients did not improve as a result of increased 
selenium, for which, there are many explanations. The dosage may not have been sufficient. 
While many clinical trials have been run, there is no laboratory model of sepsis and a paucity 
of experimental studies on selenium therapy, which could reveal dosing regimens that are 
not necessarily easy to test directly on patients. Timing could also play a role. While sodium 
selenite was administered at sepsis onset, this is a very loose definition based on the time of 
diagnosis. Perhaps some patients have been suffering from an infection without SIRS for a 
long time, that an immune boost would have been required at an earlier point in time. In 
addition, half of our study population received hydrocortisone, a standard therapy to 
prevent cardiovascular collapse. This immune suppressive medication could have mitigated 
the immune boosting effects of selenium in our particular group of patients. 
 
 
4.4. Selenium and infections 
 
Selenium deficiency has been associated with less favorable outcomes in HIV infected 
individuals [51] and tuberculosis patients [52]. Low levels of serum selenium in patients with 
Acquired Immune Deficiency Syndrome have been associated with decreased survival, 
decreased CD4+ Cell count and high viral load. The results hold true even after adjusting for 
antiretroviral regimen adherence and hepatitis C co-infection [53]. Similarly, the severity of 
pulmonary tuberculosis was positively correlated with low selenium levels in serum [54]. 
Supplementation with selenium and vitamin E have been shown to improve the antioxidant 
capacity in TB patients, although effects on the immune system were not elucidated [55].  
 
There is definitive evidence for the utility of selenium supplementation in various viral and 
bacterial infections [56, 57]. It is interesting to note that the most compelling data currently 
available on selenium’s immune enhancing properties are studies related to HIV, a severely 
immune compromised population. T cells are extremely sensitive to oxidative stress and the 
potential benefits from selenoenzymes most likely reside in their ability to regulate redox 
reactions [58]. There was no particular boost in immune function found in our series of 
critically ill sepsis patients given sodium selenite intravenously, despite having tested the 
individual arms of immunity. This could be, on the one hand, due to the acute nature of the 
disease, where the often sudden onset of sepsis is in stark contrast to patients who are living 
 
 34 
with chronic illnesses such as AIDS or TB. On the other hand, this could be a reflection of the 
complex, poorly understood progression of sepsis, where the immune system goes through 
phases of hyper- and hypoinflammation.  
 
 
4.5. Antioxidation and Dosing 
 
Sepsis can often be characterized also by increased reactive oxygen species, low 
endogenous antioxidative capacities, as well as reduced selenium stores. Selenoproteins are 
located in the endoplasmic reticulum and help protect cells from stress-induced apoptosis. 
Glutathione peroxidases are a large family of antioxidant enzymes, where selenium plays an 
essential role in their function. There have therefore been many trials evaluating outcomes 
in sepsis patients with selenium supplementation based on this premise, but the results are 
definitely mixed.  
 
One large meta-analysis found that supplementing with much higher dosages than what is 
recommended could potentially decrease mortality [18]. Most trials used a dosage of 
1000µg and after one study with particularly high dosages nevertheless demonstrated no 
improvement of vasopressor use, length of ICU stay or mortality [59], protocols have 
generally turned to a bolus at the start, as a way of topping up the depleted selenoenzyme 
pool, followed by continuous infusion. Our study used such a high dose regime, which was 
well tolerated by patients. Most decisively, many questions remain unanswered regarding 
the mechanisms of disease in sepsis, perhaps oxidative stress ultimately plays a much more 
minor role than expected and the emphasis lies in the immune system. 
 
 
4.6. Mechanisms of action 
 
We intended at the outset to uncover possible affected immune pathways which could 
benefit from selenium administration during severe sepsis. Despite a wide range of tested 
cytokines and comprehensive antigen challenges, selenium did not appear to boost immune 
function in a discernable fashion. Studies which shed light on mechanistic details of 
selenium’s impact on immunity are rather far and few between because of the vast number 




A mouse model of T cell-specific knockout of all selenoproteins has demonstrated a 
reduction in the number of mature T lymphocyte production [60]. In further mice models, 
dietary selenium intake has been shown to mediate immune response through the 
interferon-γ and interleukin-6 pathways [61]. A recent study involving selenoprotein F 
knockout mice concluded its importance in regulating immunoglobulin levels in the 
endoplasmic reticulum [62]. Immune function studies with a positive effect through 
selenium supplementation have largely been shown in the elderly population or individuals 
with proven selenium deficits. In contrast, our patient population suffers from a typically 
acute illness and selenium was administered parenterally, rather than as dietary 
supplementation over prolonged periods of time. Since the baseline selenium reserves in 
our patients are not known and the age ranges from the young to the old, direct 
comparisons are difficult. That being said, the neutral effect on immunity of intravenous 
sodium selenite observed here is still most likely attributed to sepsis being a complex 
immunological disease process.  
 
In patients with acute respiratory distress syndrome (ARDS), selenium supplementation has 
shown to modulate the interleukin-6 and interleukin-1β inflammatory responses by boosting 
the antioxidation capacities in the lungs [63]. Although the respiratory mechanisms were 
improved, there was no effect on overall survival or length of ICU stay. Similarly, without a 
better understanding of disease mechanisms during sepsis, a more refined evaluation of 
how selenium affects the immune system can be difficult. 
 
 
4.7. Characteristics of the study population 
 
Our anesthesia intensive care unit admits a wide range of patients, from trauma surgery to 
the chronically ill. This inadvertently complicates the range of pre-existing conditions and 
immune capabilities at sepsis onset, making it more challenging to elucidate the benefits of 
selenium than in a homogeneous population. There have been a number of previous 
discussions on whether the best route of administration is parenteral or enteral. Given that 
critically ill patients in the ICU are often intubated, our study also differs from selenium 




It is interesting to note that European soils appear to be more depleted of selenium than 
North American soil [64], which was reflected as a relative deficiency of selenium in 
European studies done on healthy individuals [65]. Despite this finding, a large international 
antioxidant supplementation study performed by the Canadian Critical Care Trials Group, 
also did not find a therapeutic benefit [4]. In addition, irrespective of the overall lower 
selenium levels in Europeans, sepsis patients have a definite deficit given the inflammatory 
nature of the disease. 
 
 
4.8. Strengths and weaknesses 
 
This double blinded, randomized prospective clinical trial (SISPCT) has a robust design and 
high rate of adherence to protocol. This is also a very specifically defined patient population 
meeting stringent sepsis criteria in an intensive care setting and the efficacy of high dose 
intravenous selenium was compared to placebo. The characteristics of the selenium and 
control groups are comparable and blood samples were collected over a three-week period. 
The whole blood assays gave high fidelity cytokine readouts after antigen challenge, an 
effective and proven method to yield a snapshot of immune function. To our best 
knowledge, ours is the first of its kind to examine immune function of severe sepsis patients 
receiving high dose selenium therapy. To have clinical data over a three-week period in an 
intensive care setting also provides information on the intervention’s effectiveness over 
time. To preserve the integrity of the individual datapoints without excluding outliers or 
extrapolating, we utilized the generalized least squares model to effectively compensate for 
the high rate of attrition over time. This complex statistical tool makes our conclusions much 
more reliable than conventional methods. 
 
One obvious limitation of our study is the cohort size, starting at 76 patients, this 
unfortunately drops significantly by the end of the 3 weeks given the nature of the patient 
population. Ex vivo blood samples were collected as soon as possible upon enrolment and at 
the subsequent time points, but the laboratory processing was not immediate due to 
staffing constraints. This limited the choice of immune assays available, rendering more cell-
specific tests or higher resolution of results difficult. Furthermore, the quantity of patient 
blood available also restricted the possible analyses, for example, western blots and cell 
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separation techniques were not feasible. Such experiments could have shed more light on 
mechanisms of action and altered signaling pathways. The heterogeneity of the group is 
fairly large, with a range of pathogens as well as non-microbiologically proven infections. 
Patients were admitted from both medical and surgical services, with varying pre-existing 
conditions that could be better subcategorized given a larger sample size. All statistical 
models become more powerful with lower attrition rates, to have patients followed up 
further outside of the ICU would yield a more complete data set.  
 
 
4.9. Future directions 
 
The benefits of selenium administration in boosting immunity have been explored with 
mixed results, its utility partially demonstrated in select pathogens. With our study, we 
obtained a first glimpse into the immune function in patients who are critically ill with 
severe sepsis and observed no beneficial effects of selenium. Given the relative low cost of 
selenium and the high mortality rate of severe sepsis, this is a therapy option worth 
pursuing.  
 
There have been many clinical studies on outcomes but experimental studies using sepsis 
models are lacking. This would be important in shedding light on mechanistic details of how 
exactly the large number of selenoproteins influence lymphocyte function. It would 
contribute to optimizing dosing without reaching toxicity. The research that has been carried 
out in selenium supplementation related to HIV would be relevant, in that both diseases 
embody an immunocompromised state. Glutathione peroxidase and specific antioxidant 
selenoenzymes have been implicated as key players in lymphocyte proliferation, their 
functions and levels in severe sepsis patients would offer further useful insights. 
 
Future trials could have more targeted patient profiles, where the elderly or only non-
surgical ICUs with severe sepsis are examined. With a large enough sample size, perhaps 
pathogens can be stratified, where selenium supplementation would be helpful only with 
certain types of infections. Last but not least, therapy options can be better devised when 
there is a thorough understanding of the illness at hand. Therefore, it is essential to make 
progress in understanding the immune function during sepsis at its different stages in order 
to treat it.  
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Sepsis is a complex disease process with a high mortality rate and characterized by a 
breakdown of immune system function that is not yet completely understood. Selenium is a 
trace element important in enzymes which protects against oxidative stress, an 
immunological process seen in septic patients. While selenium has been administered to 
critically ill patients for decades, the outcomes according to the literature have been mixed 
in terms of clinical benefits. In this longitudinal study using whole blood samples from septic 
patients, we performed immune function assays to uncover whether selenium 




Our patient cohort consists of data collected at the University of Munich anesthesiological 
ICUs as part of the randomized, double blinded multicenter clinical trial SISPCT (registered 
with www.clinicaltrials.gov NCT00832039). Blood samples were collected upon sepsis onset 
(day 0) and subsequently at days 4, 7, 14, and 21. They were then incubated with a wide 
range of stimulating antigens such as bacteria or viruses and the supernatants were 
retrieved for cytokine measurements. A representative panel of cytokines were selected to 
reflect the function of different immune pathways. The statistical analysis utilized a 
generalized least squares model using the software R to compensate for missing values over 




76 severe sepsis patients were enrolled at our center, 40 of which were randomized to 
receive selenium and 36 placebo. No statistically significant difference was seen in the 
immune response assay readouts between the two groups at any time point over the 21-day 
study period. There was, however, initial dampening of cytokine release at sepsis onset seen 









High dose intravenous sodium selenite administration over a three-week period did not 
improve cytokine release in ex vivo stimulated sepsis patient blood samples. While the 
immune system is impacted by the availability of selenoproteins, there was no discernable 
benefit associated with selenium supplementation in those critically ill with sepsis. This 
further reinforces the complexity of immune responses that occur during sepsis, which 
include hyper as well as hypoinflammatory phases. The decision to administer sodium 
selenite in such a setting should therefore be considered carefully by the physician team, 
taking into account the possible side effects such as nausea and vomiting, fatigue, 










Sepsis ist ein komplexes Krankheitsbild mit einer hohen Mortalitätsrate, das von einem noch 
nicht ganz verstandenen Zusammenbruch des Immunsystems geprägt ist. Selen ist ein 
Spurenelement mit großer Bedeutung für Enzyme, die gegen oxidativen Stress schützen, 
einen in Sepsis-Patienten beobachteten immunologischen Prozess. Zwar ist Selen schon 
jahrzehntelang kritisch kranken Patienten verabreicht worden, die Ergebnisse hinsichtlich 
des klinischen Nutzens sind der Literatur nach jedoch gemischt gewesen. In dieser 
Längsschnittuntersuchung von Blutproben von Sepsis-Patienten haben wir Immunfunktions-





Unsere Patientenkohorte besteht aus Daten, die an den anästhesiologischen 
Intensivstationen der Universität München im Rahmen der randomisierten, doppelblinden, 
multizentrischen klinischen Studie SISPCT erhoben worden sind (registriert 
bei www.clinicaltrials.gov, NCT00832039). Blutproben wurden beim Ausbruch von Sepsis 
genommen (Tag 0) und im Anschluss an den Tagen 4, 7, 14 und 21. Sie wurden dann mit 
einer Reihe stimulierender Antigene wie beispielsweise Bakterien oder Viren inkubiert, und 
die Überstände wurden für Zytokinmessungen gewonnen. Ein repräsentatives Panel von 
Zytokinen wurde ausgewählt, um die Funktion verschiedener Stränge des Immunsystems zu 
abzubilden. Die statistische Analyse basiert auf einem Modell der kleinsten Quadrate 
(Generalized Least Squares Model) mit Hilfe der Software R, um über die Zeit fehlende 




76 Patienten mit schwerer Sepsis waren in unserem Zentrum registriert, von 
denen randomisiert 40 für die Gabe von Selen und 36 für die Gabe von Placebo ausgewählt 
wurden. Es wurde zu keinem Zeitpunkt über die 21 Tage der Studie ein statistisch 
signifikanter Unterschied in den Ergebnissen der Immunantwort-Assays zwischen den zwei 
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Gruppen beobachtet. Es wurde allerdings in beiden Gruppen einer anfänglichen Dämpfung 
der Zytokinausschüttung beim Ausbruch von Sepsis beobachtet, der sich mit der Zeit in 




Hochdosierte intravenöse Gabe von Natriumselenit über einen Zeitraum von drei 
Wochen verbesserte die Zytokinausschüttung in ex vivo stimulierten Blutproben von Sepsis-
Patienten nicht. Obwohl das Immunsystem von der Verfügbarkeit von Selenoproteinen 
beeinflusst wird, war mit der Gabe von Selen in kritisch kranken Sepsis-Patienten kein 
erkennbarer Nutzen verbunden. Das unterstreicht die Komplexität der bei Sepsis 
auftretenden Immunantworten, die sowohl hyper- als auch hypoinflammatorische Phasen 
umfassen. Die Entscheidung zur Gabe von Natriumselenit in solch einer Situation sollte von 
dem Team der behandelnden Ärzte daher gründlich abgewogen werden, auch unter 
Berücksichtigung der möglichen Nebenwirkungen wie Übelkeit und Erbrechen, Müdigkeit, 
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9. GLS Modelling Tables 
 
The following are tabulated raw outputs generated by the statistical model ‘generalized 
least squares’ using the software R using the immune assay data and were referred to in the 
results section. Shown in the tables are regression coefficients generated with 
accompanying p-values. Day 0 of the placebo group was used as the intercept and 
comparison to all later time points as well as the selenium group. 
 
 













































































































Ich erkläre hiermit an Eides statt, 
 




„Immunological effects of intravenous selenium 
administration in severe sepsis” 
 
 
selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und 
alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als 
solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln 
nachgewiesen habe. 
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in 















Reprinted with permission. 
 
 
 55 
 
 
 
 
 
 56 
 
 
 
 
 
 57 
 
 
 
 
 
 58 
 
  
 
 59 
 
 
 
 
 
 
 
 
 
 60 
 
 
 
 
 
 
 
 
 61 
 
 
 
 
 
 
 
 
 
 62 
 
 
 
 
 
 
 
 
 
 63 
 
 
 
 
 
 
 
 
 
 64 
 
 
 
 
 
 
 
 
 
 65 
 
 
 66 
 
 
 
 
 
 
 
 
 67 
 
 
 
 
 
 
 
 
 68 
 
 
 
 
 
 
 
 
 
 69 
 
 
 
 
 
 
 
 
 
 70 
 
 
 
 
